Pure Global

Effects of 4-AP on Functional SCI Recovery - Trial NCT05447676

Access comprehensive clinical trial information for NCT05447676 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shirley Ryan AbilityLab and is currently Recruiting. The study focuses on Spinal Cord Injury. Target enrollment is 44 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05447676
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05447676
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Effects of 4-AP on Functional SCI Recovery
Effects of 4-AP on Functional Recovery After Spinal Cord Injury

Study Focus

Spinal Cord Injury

Dalfampridine

Interventional

drug

Sponsor & Location

Shirley Ryan AbilityLab

Chicago, United States of America

Timeline & Enrollment

Phase 1

Jun 30, 2022

Jun 01, 2025

44 participants

Primary Outcome

Change in TMEPs,Change in MVC

Summary

The purpose of this study is to test a strategy to potentiate functional recovery of lower
 limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug,
 Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity
 (STDP) stimulation and STDP stimulation with limb training.

ICD-10 Classifications

Sequelae of injury of spinal cord
Other injury of lumbar spinal cord
Injury of spinal cord, level unspecified
Other and unspecified injuries of thoracic spinal cord
Other and unspecified injuries of cervical spinal cord

Data Source

ClinicalTrials.gov

NCT05447676

Non-Device Trial